Fineline Cube

Follow:
14486 Articles
Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study
CompanyDrug

Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study

Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer
CompanyDrug

Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer

Gene Cradle's GC310 Receives Tacit Approval from NMPA for Wilson's Disease
CompanyDrug

Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease

Hanx Biopharmaceuticals Gains NMPA Approval for HX044 Clinical Trials
CompanyDrug

Hanx Biopharmaceuticals Gains NMPA Approval for HX044 Clinical Trials

Likang Life Sciences Gains FDA Approval for LK101 Clinical Trials
CompanyDrug

Likang Life Sciences Gains FDA Approval for LK101 Clinical Trials

CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition
CompanyDeals

CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition

EMA Committee Backs Subcutaneous Rybrevant for Lung Cancer Treatment
CompanyDrug

EMA Committee Backs Subcutaneous Rybrevant for Lung Cancer Treatment

Akeso Completes Enrollment for Global Phase III Trial of Ivonescimab in Lung Cancer
CompanyDrug

Akeso Completes Enrollment for Global Phase III Trial of Ivonescimab in Lung Cancer

Bayer Files for EMA Approval of Kerendia for Heart Failure
CompanyDrug

Bayer Files for EMA Approval of Kerendia for Heart Failure

Boston Scientific Posts Strong Q4 and Full-Year 2024 Results
Company

Boston Scientific Posts Strong Q4 and Full-Year 2024 Results

Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange
CompanyDeals

Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange

NHSA Regulates DRG/DIP Payment Methods Under '1+3+N' System
Policy / Regulatory

NHSA Regulates DRG/DIP Payment Methods Under ‘1+3+N’ System